Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amir Kashani

Ophthalmology Baltimore, MD Medical Doctor

NPI 1659425601 CMS profile 75222

600 N Wolfe St, Ste 110, Baltimore, MD 21287

Open in the dashboard

General payments

$50,124

35 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amir Kashani of Baltimore, MD is reported in the CMS Open Payments database as having received $50,124 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,625 7
2024 General $5,111 3
2023 General $336 2
2022 General $1,970 2
2021 General $11,118 10
2020 General $53 1
2019 General $18,909 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amir Kashani
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Amir Kashani were reported at $12,625. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Amir Kashani Ophthalmology median Middle half National median
2019 $18,909 $258 $104–$655 $163
2020 $53 $126 $45–$321 $114
2021 $11,118 $205 $76–$534 $132
2022 $1,970 $266 $100–$678 $149
2023 $336 $308 $117–$745 $160
2024 $5,111 $340 $127–$846 $164
2025 $12,625 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Carl Zeiss Meditec, Inc. $22,635 15 payments
  2. Abbott Laboratories $11,118 10 payments
  3. Alcon Research LLC $10,000 2 payments
  4. Genentech USA, Inc. $6,125 5 payments
  5. Alcon Vision LLC $213 1 payment
  6. Eyevance Pharmaceuticals LLC $20 1 payment
  7. Pfizer Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,275 7 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $13,000 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,950 3 payments
  4. Travel and Lodging $7,052 12 payments
  5. Food and Beverage $816 9 payments
  6. Gift $16 1 payment
  7. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. CIRRUS HD-OCT Optical Tomographer $18,882 8 payments
  2. AMPLATZER Occluders $11,118 10 payments
  3. SUSVIMO $6,125 5 payments
  4. CIRRUS HD-OCT Optical Tomography $1,950 1 payment
  5. FORUM $1,950 1 payment
  6. VisuMax $1,500 1 payment
  7. CIRRUS HD-OCT Optical Tomography $1,500 1 payment
  8. CALLISTO eye $1,500 1 payment
  9. QUATERA 700 $1,500 1 payment
  10. PLEX Elite $235 3 payments
  11. Other $326 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

65

Median for Ophthalmology: 891

Drug cost

$2,374

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 25 $1,224
Ketorolac Tromethamine Generic 40 $1,150

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$644,026

Of which drugs: $491,345

Medicare patients

414

Average age 78

Services billed

9,113

231 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 51%
Ischemic heart disease 32%
Diabetes 29%
Cancer 22%
Chronic kidney disease 21%
Osteoporosis 21%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 48 446 $290,748
Injection, faricimab-svoa, 0.1 mg J2777 Office 15 6,240 $171,125

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record